MR-T2-weighted signal intensity: a new imaging biomarker of prostate cancer aggressiveness

Computer Methods in Biomechanics and Biomedical Engineering: Imaging and Visualization

Volumn 4, Issue 3-4, 2016, Pages 130-134

  Giannini, V ^a   Vignati, A ^a   Mirasole, S ^a   Mazzetti, S ^a   Russo, F ^a   Stasi, M ^a   Regge, D ^a  

^a CANDIOLO CANCER INSTITUTE   (Italy)

Author keywords

endorectal MR imaging; prostate cancer; T2 weighted MR images; tumour aggressiveness

Indexed keywords

BIOMARKERS; BIOPSY; MAGNETIC RESONANCE; MAGNETIC RESONANCE IMAGING; PATIENT TREATMENT; RISK ASSESSMENT; TUMORS; UROLOGY;

CLINICAL COURSE; ENDORECTAL MAGNETIC RESONANCE IMAGING; GLEASON SCORES; IMAGING BIOMARKERS; METASTATIC DISEASE; PROSTATE CANCERS; SIGNAL INTENSITIES; T2 WEIGHTED; T2-WEIGHTED MAGNETIC RESONANCE IMAGE; TUMOR AGGRESSIVENESS;

DISEASES;

BIOLOGICAL MARKER; PROSTATE SPECIFIC ANTIGEN;

ARTICLE; CANCER RADIOTHERAPY; CELL HETEROGENEITY; CLINICAL ARTICLE; GLEASON SCORE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INFORMATION PROCESSING; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; TUMOR VOLUME;

EID: 84981363507     PISSN: 21681163     EISSN: 21681171     Source Type: Journal    
DOI: 10.1080/21681163.2014.910476     Document Type: Article

References (21)

1. H.U.Ahmed, M.Arya, A.Freeman, M.Emberton. 2012. Do low-grade and low-volume prostate cancers bear the hallmarks of malignancy?Lancet Oncol.13(11):e509–e517.
2. H.Bae, S.Yoshida, Y.Matsuoka, H.Nakajima, I.EIto, H.Tanaka, M.Oya, T.Nakayama, H.Takeshita, T.Kijima, et al. 2013. Apparent diffusion coefficient value as a biomarker reflecting morphological and biological features of prostate cancer. Int Urol Nephrol. 46(3):555–561.
3. J.O.Barentsz, J.Richenberg, R.Clements, P.Choyke, S.Verma, G.Villeirs, O.Rouviere, V.Logager, J.J.Fütterer2012. ESUR prostate MR guidelines 2012. Eur Radiol.22(4):746–757.
4. V.Giannini, A.Vignati, L.Morra, D.Persano, D.Brizzi, L.Carbonaro, A.Bert, F.Sardanelli, D.Regge. 2010. A fully automatic algorithm for segmentation of the breasts in DCE-MR images. Conf Proc IEEE Eng Med Biol Soc.2010:3146–3149.
5. T.Hambrock, D.M.Somford, H.J.Huisman. 2011. Relationship between apparent diffusion coefficients at 3.0-T MR imaging and Gleason grade in peripheral zone prostate cancer. Radiology. 259(2):453–461.
6. A.Heidenreich, J.Bellmunt, M.Bolla, S.Joniau, M.Mason, V.Matveev, N.Mottet, H.P.Schmid, T.van der Kwast, T.Wiegel, et al. 2011. EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. Eur Radiol.59(1):61–71.
7. C.M.Hoeks, J.O.Barentsz, T.Hambrock, D.Yakar, D.M.Somford, S.W.Heijmink, T.W.Scheenen, P.C.Vos, H.Huisman, I.M.van Oort, et al. 2011. Prostate cancer: multiparametric MR imaging for detection, localization, and staging. Radiology. 261:46–66.
8. S.K.Hong, B.K.Han, S.T.Lee, S.S.Kim, K.E.Min, S.J.Jeong, H.Jeong, S.S.Byun, H.J.Lee, G.Choe, S.E.Lee2009. Prediction of Gleason score upgrading in low-risk prostate cancers diagnosed via multi (> or = 12)-core prostate biopsy. World J Urol.27(2):271–276.
9. J.S.Jones, A.Patel, L.Schoenfield, J.C.Rabets, C.D.Zippe, C.Magi-Galluzzi. 2006. Saturation technique does not improve cancer detection as an initial prostate biopsy strategy. J Urol.175(2):485–488.
10. S.I.Jung, O.F.Donati, H.A.Vargas, D.Goldman, H.Hricak, O.Akin2013. Transition zone prostate cancer: incremental value of diffusion-weighted endorectal MR imaging in tumor detection and assessment of aggressiveness. Radiology. 269(2):493–503.
11. L.Klotz. 2012. Cancer overdiagnosis and overtreatment. Curr Opin Urol.22(3):203–209.
12. R.Montironi, A.Lopez-Beltran, R.Mazzucchelli, M.Scarpelli, E.Bollito. 2001. Assessment of radical prostatectomy specimens and diagnostic reporting of pathological findings. Pathologica. 93:226–232.
13. R.Montironi, R.Mazzucchelli, T.Kwast. 2003. Morphological assessment of radical prostatectomy specimens. A protocol with clinical relevance. Virchows Arch.442:211–217.
14. J.C.Nickel, M.Speakman. 2012. Should we really consider Gleason 6 prostate cancer?BJU Int.109(5):645–646.
15. A.B.Rosenkrantz, E.E.Sigmund, G.Johnson, J.S.Babb, T.C.Mussi, J.Melamed, S.S.Taneja, V.S.Lee, J.H.Jensen. 2012. Prostate cancer: feasibility and preliminary experience of a diffusional kurtosis model for detection and assessment of aggressiveness of peripheral zone cancer. Radiology. 264(1):126–135.
16. B.Turkbey, P.S.Albert, K.Kurdziel, P.L.Choyke2009. Imaging localized prostate cancer: current approaches and new developments. AJR Am J Roentgenol.192(6):1471–1480.
17. N.J.Tustison, B.B.Avants, P.A.Cook, Y.Zheng, A.Egan, P.A.Yushkevich, J.C.Gee. 2010. N4ITK: improved N3 bias correction. IEEE Trans Med Imaging.29(6):1310–1320.
18. S.Viswanath, D.Palumbo, J.Chappelow, P.Patel, B.N.Bloch, N.Rofsky, R.Lenkinski, E.Genega, A.Madabhushi. 2011. Empirical evaluation of bias field correction algorithms for computer-aided detection of prostate cancer on T2w MRI. In: R.M.Summers, B.Van Ginneken, editors. Medical imaging 2011: computer aided diagnosis. Proceedings of SPIE, Vol. 7963, Lake Buena Vista, Orlando (FL), 12–17February 2011, SPIE.
19. E.K.Vos, G.J.Litjens, T.Kobus, T.Hambrock, C.A.Hulsbergen-van de Kaa, J.O.Barentsz, H.J.Huisman, T.W.Scheenen2013. Assessment of prostate cancer aggressiveness using dynamic contrast-enhanced magnetic resonance imaging at 3 T. Eur Urol.64(3):448–455.
20. L.Wang, Y.Mazaheri, J.Zhang, N.M.Ishill, K.Kuroiwa, H.Hricak2008. Assessment of biologic aggressiveness of prostate cancer: correlation of MR signal intensity with Gleason grade after radical prostatectomy. Radiology. 246(1):168–176.
21. S.S.Willard, S.Koochekpour. 2012. Regulators of gene expression as biomarkers for prostate cancer. Am J Cancer Res.2(6):620–657.